New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
October 2, 2018 - Paratek Pharmaceuticals and Almirall announced the FDA approval of Seysara (sarecycline), for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.
Download PDF
Return to publications
